KR20250079249A - 암 치료를 위한 조합 치료법 - Google Patents

암 치료를 위한 조합 치료법 Download PDF

Info

Publication number
KR20250079249A
KR20250079249A KR1020257017723A KR20257017723A KR20250079249A KR 20250079249 A KR20250079249 A KR 20250079249A KR 1020257017723 A KR1020257017723 A KR 1020257017723A KR 20257017723 A KR20257017723 A KR 20257017723A KR 20250079249 A KR20250079249 A KR 20250079249A
Authority
KR
South Korea
Prior art keywords
ser
antibody
val
thr
gly
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020257017723A
Other languages
English (en)
Korean (ko)
Inventor
제임스 바셀리
존 마크 위긴턴
에지오 본비니
스코트 쾨니그
Original Assignee
마크로제닉스, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 마크로제닉스, 인크. filed Critical 마크로제닉스, 인크.
Publication of KR20250079249A publication Critical patent/KR20250079249A/ko
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020257017723A 2015-10-08 2016-10-06 암 치료를 위한 조합 치료법 Pending KR20250079249A (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562239020P 2015-10-08 2015-10-08
US62/239,020 2015-10-08
KR1020187012875A KR20180084772A (ko) 2015-10-08 2016-10-06 암 치료를 위한 조합 치료법
PCT/US2016/055750 WO2017062619A2 (en) 2015-10-08 2016-10-06 Combination therapy for the treatment of cancer

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020187012875A Division KR20180084772A (ko) 2015-10-08 2016-10-06 암 치료를 위한 조합 치료법

Publications (1)

Publication Number Publication Date
KR20250079249A true KR20250079249A (ko) 2025-06-04

Family

ID=58488465

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020187012875A Ceased KR20180084772A (ko) 2015-10-08 2016-10-06 암 치료를 위한 조합 치료법
KR1020257017723A Pending KR20250079249A (ko) 2015-10-08 2016-10-06 암 치료를 위한 조합 치료법

Family Applications Before (1)

Application Number Title Priority Date Filing Date
KR1020187012875A Ceased KR20180084772A (ko) 2015-10-08 2016-10-06 암 치료를 위한 조합 치료법

Country Status (18)

Country Link
US (2) US11174315B2 (enExample)
EP (1) EP3359192A4 (enExample)
JP (2) JP7320944B2 (enExample)
KR (2) KR20180084772A (enExample)
CN (1) CN108136010A (enExample)
AU (1) AU2016334041B2 (enExample)
BR (1) BR112018006817A2 (enExample)
GE (1) GEP20217317B (enExample)
HK (1) HK1251475A1 (enExample)
IL (1) IL258521B2 (enExample)
MA (1) MA45429A (enExample)
MX (2) MX2018004177A (enExample)
PH (1) PH12018500692A1 (enExample)
RU (1) RU2731202C2 (enExample)
TW (1) TWI859113B (enExample)
UA (1) UA128469C2 (enExample)
WO (1) WO2017062619A2 (enExample)
ZA (1) ZA201801797B (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013173223A1 (en) * 2012-05-15 2013-11-21 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting pd-1/pd-l1 signaling
SI3328419T1 (sl) * 2015-07-30 2021-11-30 Macrogenics, Inc. PD-1-vezavne molekule in postopki uporabe le-teh
KR20180038045A (ko) * 2015-08-17 2018-04-13 마크로제닉스, 인크. B7-h3과 cd3에 결합할 수 있는 이중특이적 1가 디아바디, 및 그것의 사용
AU2016370376B2 (en) 2015-12-14 2023-12-14 Macrogenics, Inc. Bispecific molecules having immunoreactivity with PD-1 and CTLA-4, and methods of use thereof
US10961311B2 (en) 2016-04-15 2021-03-30 Macrogenics, Inc. B7-H3 binding molecules, antibody drug conjugates thereof and methods of use thereof
FR3064007A1 (fr) * 2017-03-20 2018-09-21 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Anticorps pour le traitement de cancers
EP3618863B1 (en) 2017-05-01 2023-07-26 Agenus Inc. Anti-tigit antibodies and methods of use thereof
TWI832818B (zh) * 2017-07-07 2024-02-21 南韓商韓美藥品股份有限公司 新穎的治療性酵素融合蛋白及其用途
US12435328B2 (en) 2017-12-22 2025-10-07 Hanmi Pharm. Co., Ltd. Therapeutic enzyme fusion protein having a novel structure and use thereof
CN120714025A (zh) 2018-06-20 2025-09-30 因赛特公司 抗pd-1抗体及其用途
JP7682789B2 (ja) * 2018-11-16 2025-05-26 アルバート アインシュタイン カレッジ オブ メディスン Ｂ７－Ｈ３のＩｇＶドメインに対するモノクローナル抗体及びその使用
JP7753186B2 (ja) * 2019-08-02 2025-10-14 シーティーティーキュー－アケソ（シャンハイ） バイオメド テク カンパニー リミテッド 抗ｐｄ－１抗体およびその医学的使用
CA3177550A1 (en) * 2020-05-27 2021-12-02 Dana-Farber Cancer Institute, Inc. Bispecific molecules for selectively modulating t cells
AR125753A1 (es) 2021-05-04 2023-08-09 Agenus Inc Anticuerpos anti-tigit, anticuerpos anti-cd96 y métodos de uso de estos
CN113999320B (zh) * 2021-11-02 2022-09-27 深圳先进技术研究院 以cd28和4-1bb为共刺激结构域的靶向cd276的嵌合抗原受体及其应用

Family Cites Families (151)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3862925A (en) 1973-07-05 1975-01-28 American Home Prod Preparation of somatotropin release inhibiting factor and intermediates therefor
US3842067A (en) 1973-07-27 1974-10-15 American Home Prod Synthesis of(des-asn5)-srif and intermediates
JPS5726506B2 (enExample) 1974-03-08 1982-06-04
US4105603A (en) 1977-03-28 1978-08-08 The Salk Institute For Biological Studies Peptides which effect release of hormones
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US4880078A (en) 1987-06-29 1989-11-14 Honda Giken Kogyo Kabushiki Kaisha Exhaust muffler
AU6290090A (en) 1989-08-29 1991-04-08 University Of Southampton Bi-or trispecific (fab)3 or (fab)4 conjugates
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
ATE221379T1 (de) 1991-05-01 2002-08-15 Jackson H M Found Military Med Verfahren zur behandlung infektiöser respiratorischer erkrankungen
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
GB9112536D0 (en) 1991-06-11 1991-07-31 Celltech Ltd Chemical compounds
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
GB9115364D0 (en) 1991-07-16 1991-08-28 Wellcome Found Antibody
CA2078539C (en) 1991-09-18 2005-08-02 Kenya Shitara Process for producing humanized chimera antibody
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US5934272A (en) 1993-01-29 1999-08-10 Aradigm Corporation Device and method of creating aerosolized mist of respiratory drug
US6180377B1 (en) 1993-06-16 2001-01-30 Celltech Therapeutics Limited Humanized antibodies
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US6019968A (en) 1995-04-14 2000-02-01 Inhale Therapeutic Systems, Inc. Dispersible antibody compositions and methods for their preparation and use
US6265150B1 (en) 1995-06-07 2001-07-24 Becton Dickinson & Company Phage antibodies
DK0885002T3 (da) 1996-03-04 2011-08-22 Penn State Res Found Materialer og fremgangsmåder til forøgelse af cellulær internalisering
US5985309A (en) 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
US5855913A (en) 1997-01-16 1999-01-05 Massachusetts Instite Of Technology Particles incorporating surfactants for pulmonary drug delivery
US5874064A (en) 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US5922845A (en) 1996-07-11 1999-07-13 Medarex, Inc. Therapeutic multispecific compounds comprised of anti-Fcα receptor antibodies
JP4219985B2 (ja) 1996-07-23 2009-02-04 タノックス ファーマ ベスローテン フェンノートシャップ 二つの共刺激経路を同時にブロックできる可溶性分子を用いたｔ細胞寛容の誘導
DE69730038T2 (de) 1996-08-16 2004-11-25 The President And Fellows Of Harvard College, Cambridge Lösliche monovalente und multivalente mhc klasse ii fusionsproteine und deren verwendungen
DK0826696T3 (da) 1996-09-03 2002-09-23 Gsf Forschungszentrum Umwelt Anvendelse af bi- og trispecifikke antistoffer til inducering af en tumorimmunitet
WO1998023289A1 (en) 1996-11-27 1998-06-04 The General Hospital Corporation MODULATION OF IgG BINDING TO FcRn
EP0846571B1 (en) 1996-12-04 2001-04-11 Agfa-Gevaert N.V. Method for the formation of an improved heat mode image
ATE287257T1 (de) 1997-01-16 2005-02-15 Massachusetts Inst Technology Zubereitung von partikelhaltigen arzneimitteln zur inhalation
US20020062010A1 (en) 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
DK0979281T3 (da) 1997-05-02 2005-11-21 Genentech Inc Fremgangsmåde til fremstilling af multispecifikke antistoffer med heteromultimere og fælles bestanddele
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
CA2321262A1 (en) 1998-02-19 1999-08-26 President And Fellows Of Harvard College Monovalent, multivalent, and multimeric mhc binding domain fusion proteins and conjugates, and uses therefor
AU747231B2 (en) 1998-06-24 2002-05-09 Alkermes, Inc. Large porous particles emitted from an inhaler
WO2000018806A1 (de) 1998-09-25 2000-04-06 Horst Lindhofer Bispezifische und trispezifische antikörper, die spezifisch mit induzierbaren oberflächenantigenen als operationelle zielstrukturen reagieren
ATE255420T1 (de) 1998-09-25 2003-12-15 Horst Lindhofer Verwendung von tumorzellen zeitversetzt in kombination mit intakten antikörpern zur immunisierung
AU784062B2 (en) 1999-08-23 2006-01-19 Dana-Farber Cancer Institute, Inc. Novel B7-4 molecules and uses therefor
WO2001014557A1 (en) 1999-08-23 2001-03-01 Dana-Farber Cancer Institute, Inc. Pd-1, a receptor for b7-4, and uses therefor
PT1234031T (pt) 1999-11-30 2017-06-26 Mayo Foundation B7-h1, uma nova molécula imunoregulatória
US6803192B1 (en) 1999-11-30 2004-10-12 Mayo Foundation For Medical Education And Research B7-H1, a novel immunoregulatory molecule
CN1406249B (zh) 2000-02-11 2010-06-16 默克专利股份有限公司 增加基于抗体的融合蛋白的循环半衰期
US20030031675A1 (en) 2000-06-06 2003-02-13 Mikesell Glen E. B7-related nucleic acids and polypeptides useful for immunomodulation
MXPA02012106A (es) 2000-06-06 2003-06-06 Bristol Myers Squibb Co Polipeptidos y acidos nucleicos relacionados con b7 empleados para inmunomodulacion.
WO2002010187A1 (en) 2000-07-27 2002-02-07 Mayo Foundation For Medical Education And Research B7-h3 and b7-h4, novel immunoregulatory molecules
DE10043437A1 (de) 2000-09-04 2002-03-28 Horst Lindhofer Verwendung von trifunktionellen bispezifischen und trispezifischen Antikörpern zur Behandlung von malignem Aszites
US8501471B2 (en) 2000-10-18 2013-08-06 Sloan-Kettering Institute For Cancer Research Uses of monoclonal antibody 8H9
US7740845B2 (en) 2000-10-18 2010-06-22 Sloan-Kettering Institute For Cancer Research Uses of monoclonal antibody 8H9
US7666424B2 (en) 2001-10-17 2010-02-23 Sloan-Kettering Institute For Cancer Research Methods of preparing and using single chain anti-tumor antibodies
CA2423843A1 (en) 2000-10-18 2002-04-25 Sloan-Kettering Institute For Cancer Research Uses of monoclonal antibody 8h9
US8414892B2 (en) 2000-10-18 2013-04-09 Sloan-Kettering Institute For Cancer Research Uses of monoclonal antibody 8H9
US7737258B2 (en) 2000-10-18 2010-06-15 Sloan-Kettering Institute For Cancer Research Uses of monoclonal antibody 8H9
ES2649037T3 (es) 2000-12-12 2018-01-09 Medimmune, Llc Moléculas con semividas prolongadas, composiciones y usos de las mismas
US7794710B2 (en) 2001-04-20 2010-09-14 Mayo Foundation For Medical Education And Research Methods of enhancing T cell responsiveness
JP4249013B2 (ja) 2001-07-31 2009-04-02 佑 本庶 Ｐｄ−１に対し特異性を有する物質
CA2466279A1 (en) 2001-11-13 2003-05-22 Dana-Farber Cancer Institute, Inc. Agents that modulate immune cell activation and methods of use thereof
IL149820A0 (en) 2002-05-23 2002-11-10 Curetech Ltd Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency
DE60335022D1 (de) 2002-06-19 2010-12-30 Raven Biotechnologies Inc Internalisierende Antikörper spezifisch für das RAAG10 Zelloberflächenziel
US7595048B2 (en) 2002-07-03 2009-09-29 Ono Pharmaceutical Co., Ltd. Method for treatment of cancer by inhibiting the immunosuppressive signal induced by PD-1
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
BR0316880A (pt) 2002-12-23 2005-10-25 Wyeth Corp Anticorpos contra pd-1 e usos dos mesmos
US7960512B2 (en) 2003-01-09 2011-06-14 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
JP2006524039A (ja) 2003-01-09 2006-10-26 マクロジェニクス，インコーポレーテッド 変異型Ｆｃ領域を含む抗体の同定および作製ならびにその利用法
WO2004072286A1 (ja) 2003-01-23 2004-08-26 Ono Pharmaceutical Co., Ltd. ヒトｐｄ−１に対し特異性を有する物質
US20050002935A1 (en) 2003-04-17 2005-01-06 Vincent Ling Use of B7-H3 as an immunoregulatory agent
AU2004290070A1 (en) 2003-11-12 2005-05-26 Biogen Idec Ma Inc. Neonatal Fc receptor (FcRn)-binding polypeptide variants, dimeric Fc binding proteins and methods related thereto
JP4906094B2 (ja) 2004-01-16 2012-03-28 リジェネロン・ファーマシューティカルズ・インコーポレイテッド レセプターを活性化し得る融合ポリペプチド
DK2412728T3 (en) 2004-08-03 2015-04-07 Innate Pharma Therapeutic compositions for cancer, that target 4Ig-B7-H3
US20070166281A1 (en) 2004-08-21 2007-07-19 Kosak Kenneth M Chloroquine coupled antibodies and other proteins with methods for their synthesis
EP1794288A1 (en) 2004-09-13 2007-06-13 VIB vzw The modulation of phagocytosis in neurons
WO2006044717A2 (en) 2004-10-15 2006-04-27 Verisign, Inc. One time password
US7632497B2 (en) 2004-11-10 2009-12-15 Macrogenics, Inc. Engineering Fc Antibody regions to confer effector function
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
US8802820B2 (en) 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
BG65954B1 (bg) 2005-01-05 2010-07-30 Чавдар ВАСИЛЕВ Средство за селективно подтискане активността на патологични автореактивни в-клетки
AU2006232310B9 (en) 2005-04-06 2011-07-21 Ibc Pharmaceuticals, Inc. Improved stably tethered structures of defined compositions with multiple functions or binding specificities
CN101484182B (zh) 2005-04-06 2014-06-11 Ibc药品公司 由同二聚体、同四聚体或二聚体的二聚体组成的稳定连接复合体的生产方法及用途
JP5838021B2 (ja) 2005-04-15 2015-12-24 マクロジェニクス，インコーポレーテッド 共有結合型ダイアボディとその使用
EP2439273B1 (en) 2005-05-09 2019-02-27 Ono Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
EP3130350A1 (en) * 2005-06-08 2017-02-15 Dana-Farber Cancer Institute, Inc. Methods and compositions for the treatment of persistent infections and cancer by inhibiting the programmed cell death 1 (pd-1)pathway
KR101888321B1 (ko) 2005-07-01 2018-08-13 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
PL1919503T3 (pl) 2005-08-10 2015-04-30 Macrogenics Inc Identyfikacja i inżynieria przeciwciał ze zmiennymi regionami FC oraz sposoby ich stosowania
EP1937851A4 (en) 2005-10-19 2010-08-25 Ibc Pharmaceuticals Inc METHOD AND COMPOSITIONS FOR PRODUCING BIOACTIVE GROUPS OF INCREASED COMPLEXITY AND THEIR USE
CA2633486C (en) 2005-12-16 2015-02-03 Ibc Pharmaceuticals, Inc. Multivalent immunoglobulin-based bioactive assemblies
CA2644903A1 (en) 2006-03-10 2007-09-20 Macrogenics, Inc. Identification and engineering of antibodies with variant heavy chains and methods of using same
ES2395969T3 (es) 2006-03-24 2013-02-18 Merck Patent Gmbh Dominios de proteínas heterodiméricas genéticamente modificados
MX380352B (es) 2006-06-12 2025-03-12 Aptevo Res & Development Llc Proteinas de union multivalentes monocatenarias con funcion efectora.
AT503889B1 (de) 2006-07-05 2011-12-15 Star Biotechnologische Forschungs Und Entwicklungsges M B H F Multivalente immunglobuline
AT503902B1 (de) 2006-07-05 2008-06-15 F Star Biotech Forsch & Entw Verfahren zur manipulation von immunglobulinen
PL2059533T3 (pl) 2006-08-30 2013-04-30 Genentech Inc Przeciwciała wieloswoiste
JP5601836B2 (ja) 2006-11-08 2014-10-08 マクロジェニックス ウエスト， インコーポレイテッド Ｔｅｓ７およびｔｅｓ７に結合する抗体
US7992748B2 (en) 2006-11-17 2011-08-09 North Safety Products, Inc. Earplug dispenser
US8652466B2 (en) 2006-12-08 2014-02-18 Macrogenics, Inc. Methods for the treatment of disease using immunoglobulins having Fc regions with altered affinities for FcγRactivating and FcγRinhibiting
NZ594510A (en) 2006-12-27 2012-06-29 Harvard College Compositions and methods for the treatment of infections and tumors
EP2121008A4 (en) 2007-03-22 2010-03-31 Sloan Kettering Inst Cancer USE OF MONOCLONAL ANTIBODY 8H9
CA2688275A1 (en) 2007-05-31 2008-12-04 Genmab A/S Stable igg4 antibodies
NZ600758A (en) 2007-06-18 2013-09-27 Merck Sharp & Dohme Antibodies to human programmed death receptor pd-1
EP2014680A1 (en) 2007-07-10 2009-01-14 Friedrich-Alexander-Universität Erlangen-Nürnberg Recombinant, single-chain, trivalent tri-specific or bi-specific antibody derivatives
US20090028857A1 (en) 2007-07-23 2009-01-29 Cell Genesys, Inc. Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof
EP2626371A1 (en) 2007-07-31 2013-08-14 MedImmune, LLC Multispecific epitope binding proteins and uses thereof
US8062852B2 (en) 2007-10-01 2011-11-22 The Children's Hospital And Regional Medical Center Detection and treatment of autoimmune disorders
WO2009073533A2 (en) 2007-11-30 2009-06-11 Medarex, Inc. Anti-b7h4 monoclonal antibody-drug conjugate and methods of use
EP2113255A1 (en) 2008-05-02 2009-11-04 f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. Cytotoxic immunoglobulin
CA2726845C (en) 2008-06-04 2017-09-26 Macrogenics, Inc. Antibodies with altered binding to fcrn and methods of using same
RS54233B1 (sr) 2008-08-25 2015-12-31 Amplimmune Inc. Kompozicije pd-1 antagonista i postupci za njihovu primenu
WO2010028796A1 (en) 2008-09-10 2010-03-18 F. Hoffmann-La Roche Ag Trispecific hexavalent antibodies
WO2010028795A1 (en) 2008-09-10 2010-03-18 F. Hoffmann-La Roche Ag Multivalent antibodies
WO2010028797A1 (en) 2008-09-10 2010-03-18 F. Hoffmann-La Roche Ag Multivalent antibodies
MX2011003195A (es) 2008-09-26 2011-08-12 Dana Farber Cancer Inst Inc Anticuerpos anti-pd-1, pd-l1 y pd-l2 humanos y usos de los mismos.
AR075896A1 (es) 2009-03-20 2011-05-04 Genentech Inc Anticuerpos anti-her (factor de crecimiento epidermico)
CN102448985B (zh) 2009-05-27 2015-08-05 霍夫曼-拉罗奇有限公司 三或四特异性抗体
JP2013512251A (ja) 2009-11-24 2013-04-11 アンプリミューン、インコーポレーテッド Ｐｄ−ｌ１／ｐｄ−ｌ２の同時阻害
GB201000467D0 (en) 2010-01-12 2010-02-24 Ucb Pharma Sa Antibodies
PH12012501751A1 (en) * 2010-03-04 2012-11-12 Macrogenics Inc Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
SG10201604336VA (en) 2010-03-04 2016-07-28 Macrogenics Inc Antibodies Reactive With B7-H3, Immunologically Active Fragments Thereof And Uses Thereof
US8876892B2 (en) 2010-04-21 2014-11-04 Medtronic, Inc. Prosthetic heart valve delivery system with spacing
KR101860963B1 (ko) 2010-04-23 2018-05-24 제넨테크, 인크. 이종다량체 단백질의 생산
WO2011143545A1 (en) 2010-05-14 2011-11-17 Rinat Neuroscience Corporation Heterodimeric proteins and methods for producing and purifying them
WO2012009544A2 (en) 2010-07-14 2012-01-19 Amgen Inc. Domain insertion immunoglobulin
AU2011325833C1 (en) 2010-11-05 2017-07-13 Zymeworks Bc Inc. Stable heterodimeric antibody design with mutations in the Fc domain
AU2012236479B2 (en) 2011-03-31 2016-10-20 Merck Sharp & Dohme Llc Stable formulations of antibodies to human programmed death receptor PD-1 and related treatments
ES2669310T3 (es) 2011-04-20 2018-05-24 Medimmune, Llc Anticuerpos y otras moléculas que se unen con B7-H1 y PD-1
PH12013502201A1 (en) 2011-04-25 2014-01-13 Daiichi Sankyo Co Ltd Anti-b7-h3 antibody
WO2012156430A1 (en) 2011-05-17 2012-11-22 Trion Research Gmbh Vaccine preparation containing trifunctional antibodies with antigen immunogenicity enhancer properties
WO2012162583A1 (en) 2011-05-26 2012-11-29 Ibc Pharmaceuticals, Inc. Design and construction of novel multivalent antibodies
US20150045540A1 (en) 2011-06-28 2015-02-12 Sea Lane Biotechnologies, Llc Multispecific stacked variable domain binding proteins
WO2013006544A1 (en) 2011-07-06 2013-01-10 Medimmune, Llc Methods for making multimeric polypeptides
US9920438B2 (en) 2011-07-07 2018-03-20 Massachusetts Institute Of Technology Methods and apparatus for ultrathin catalyst layer for photoelectrode
MX2014000578A (es) * 2011-07-14 2014-04-30 Pfizer Tratamiento con anticuerpos anti-pcsk9.
RU2604814C2 (ru) 2011-07-24 2016-12-10 Кьюртек Лтд. Варианты гуманизированных иммуномодулирующих моноклональных антител
CN103781780B (zh) 2011-07-28 2015-11-25 赛尔佐姆有限公司 作为jak抑制剂的杂环基嘧啶类似物
MY193562A (en) 2011-08-01 2022-10-19 Genentech Inc Methods of treating cancer using pd-1 axis binding antagonists and mek inhibitors
EP2776061B1 (en) 2011-11-07 2019-08-14 MedImmune, LLC Multispecific and multivalent binding proteins and uses thereof
CA2863944A1 (en) 2012-02-10 2013-08-15 Research Corporation Technologies, Inc. Fusion proteins comprising immunoglobulin constant domain-derived scaffolds
WO2013163427A1 (en) 2012-04-25 2013-10-31 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Antibodies to treat hiv-1 infection
EP2855531A1 (en) 2012-05-24 2015-04-08 F. Hoffmann-La Roche AG Multispecific antibodies
US20150203591A1 (en) 2012-08-02 2015-07-23 Regeneron Pharmaceuticals, Inc. Mutivalent antigen-binding proteins
SG11201508528TA (en) 2013-05-02 2015-11-27 Anaptysbio Inc Antibodies directed against programmed death-1 (pd-1)
CN111423511B (zh) 2013-05-31 2024-02-23 索伦托药业有限公司 与pd-1结合的抗原结合蛋白
JP6586087B2 (ja) * 2013-08-20 2019-10-02 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． Ｐｄ−１アンタゴニストとジナシクリブとの組合せでの癌治療
EP3060251A4 (en) * 2013-10-25 2017-12-06 Pharmacyclics LLC Treatment using bruton's tyrosine kinase inhibitors and immunotherapy
EA201690912A1 (ru) 2013-11-05 2016-10-31 Когнейт Биосервисис, Инк. Комбинации ингибиторов контрольных точек и терапевтических средств для лечения рака
GB201320729D0 (en) * 2013-11-25 2014-01-08 Cancer Rec Tech Ltd Therapeutic compounds and their use
FI3083686T4 (fi) * 2013-12-17 2023-05-09 Menetelmiä syöpien hoitamiseksi käyttäen pd-1-akselia sitovia antagonisteja ja taksaaneja
BR112016013963A2 (pt) * 2013-12-17 2017-10-10 Genentech Inc terapia de combinação compreendendo agonistas de ligação de ox40 e antagonistas de ligação do eixo de pd-1
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
JP2017507155A (ja) 2014-03-05 2017-03-16 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 抗ｐｄ−１抗体と他の抗癌剤の組合せを使用する腎癌の処置
TWI870335B (zh) * 2015-06-12 2025-01-21 美商宏觀基因股份有限公司 變異的嵌合4d5抗體及其與抗pd-1抗體聯合用於治療癌症的應用

Also Published As

Publication number Publication date
BR112018006817A2 (pt) 2018-10-23
AU2016334041A1 (en) 2018-04-26
RU2018111529A (ru) 2019-11-08
ZA201801797B (en) 2019-01-30
US20190389952A1 (en) 2019-12-26
WO2017062619A3 (en) 2017-05-18
MA45429A (fr) 2019-05-01
MX2022015748A (es) 2023-01-24
NZ741159A (en) 2024-12-20
WO2017062619A2 (en) 2017-04-13
JP2018536632A (ja) 2018-12-13
MX2018004177A (es) 2018-09-11
AU2016334041B2 (en) 2023-02-09
CN108136010A (zh) 2018-06-08
IL258521B2 (en) 2024-01-01
UA128469C2 (uk) 2024-07-24
JP7384945B2 (ja) 2023-11-21
RU2018111529A3 (enExample) 2020-01-09
HK1251475A1 (zh) 2019-02-01
IL258521A (en) 2018-05-31
JP2022058802A (ja) 2022-04-12
PH12018500692A1 (en) 2018-10-15
US11174315B2 (en) 2021-11-16
EP3359192A2 (en) 2018-08-15
TWI859113B (zh) 2024-10-21
EP3359192A4 (en) 2019-05-01
US20220204625A1 (en) 2022-06-30
JP7320944B2 (ja) 2023-08-04
GEP20217317B (en) 2021-11-10
TW201718013A (zh) 2017-06-01
IL258521B1 (en) 2023-09-01
RU2731202C2 (ru) 2020-08-31
KR20180084772A (ko) 2018-07-25

Similar Documents

Publication Publication Date Title
JP7384945B2 (ja) Ｂ７‐ｈ３に特異的に結合する分子及びｐｄ‐１に特異的に結合する分子
US11840571B2 (en) Methods of using bispecific molecules having immunoreactivity with PD-1 and CTLA-4
TWI691509B (zh) Ｐｄ-１結合分子和其使用方法
KR20190015520A (ko) 조합 치료법
WO2017062615A2 (en) Combination therapy for the treatment of cancer
TW201938192A (zh) 雙特異性ｃｄ１６-結合分子及其在疾病治療中的用途
JP7378567B2 (ja) Ｌａｇ‐３結合分子及びその使用方法
NZ782254A (en) Bispecific molecules having immunoreactivity with pd-1 and ctla-4, and methods of use thereof
EA043373B1 (ru) Биспецифичные молекулы, обладающие иммунореактивностью в отношении pd-1 и ctla-4, и способы их применения

Legal Events

Date Code Title Description
A107 Divisional application of patent
A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PA0302 Request for accelerated examination

St.27 status event code: A-1-2-D10-D16-exm-PA0302

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902